We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Kuros Completes Patient Recruitment in a Phase IIB Clinical Trial with Kur-211 for Diabetic Foot Ulcers
News

Kuros Completes Patient Recruitment in a Phase IIB Clinical Trial with Kur-211 for Diabetic Foot Ulcers

Kuros Completes Patient Recruitment in a Phase IIB Clinical Trial with Kur-211 for Diabetic Foot Ulcers
News

Kuros Completes Patient Recruitment in a Phase IIB Clinical Trial with Kur-211 for Diabetic Foot Ulcers

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Kuros Completes Patient Recruitment in a Phase IIB Clinical Trial with Kur-211 for Diabetic Foot Ulcers"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Kuros Biosurgery AG, has announced that it has completed recruitment in a Phase IIb clinical trial designed to investigate KUR-211 (Viz.I-020201) in the treatment of diabetic foot ulcers.

This Phase IIb clinical trial is a randomized, multi-center, controlled, parallel group dose-finding study to evaluate the efficacy and safety of KUR-211 used as an adjunct to standard of care in patients with diabetic foot ulcers.

KUR-211 is a bioactive therapy intended for topical treatment of diabetic foot ulcers, stimulating the granulation tissue formation, that aids wound closure.

The study evaluates the effects of KUR-211 applied twice a week for maximum 16 weeks in addition to standard of care versus standard of care (SOC) alone.

KUR-211 consists of a modified variant of platelet-derived growth factor (PDGF) incorporated into a fibrin sealant and is applied to the wound as a foam.

The innovative Kuros “TG-hook” technology enables the PDGF to be retained at the site for local exposure to migrating cells and for sustained delivery of PDGF on enzymatic cleavage of the matrix. It is believed that this novel approach may improve the frequency and speed of healing.

A total of 211 patients have been randomized and treated in over 27 centers across Europe including Russia. The primary endpoint of this study is percentage reduction in ulcer surface area after 4 weeks of treatment when compared to SOC alone.

Patients are followed for 7 months following initial treatment. Kuros is expecting to report the outcome of this study around the middle of 2012.

Dr. Virginia Jamieson, Chief Medical Officer of Kuros, commented: “We are very pleased to have completed recruitment for this study with KUR-211 and we look forward to reporting the results of this novel approach to the treatment of diabetic foot ulcers”.

Kuros partnered with Baxter International Inc. for the development of KUR-211 under a collaboration and license agreement that was signed in 2005.

Following the successful completion of this study, Kuros and Baxter will look for a partner that takes over responsibility for the further development of KUR-211.

Advertisement